MichaelAndreeffMDPhD
Hematology • Houston, TXHematologic Oncology
Professor of Medicine, Haas Chair in Genetics, Chief, Molecular Hematology and Therapy, U.T. MD Anderson Cancer Center
Dr. Andreeff is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Michael Andreeff is a Houston-based specialist in Hematology with a subspecialty in Hematologic Oncology. He completed his medical degree at the University of Heidelberg Faculty of Medicine in 1968 and earned his Ph.D. in Cell Biology from the University of Heidelberg Medical School. His areas of expertise include hematologic oncology, myelodysplasia, and Acute Myeloid Leukemias. He has been a pioneer in Flow Cytometry and has developed numerous agents which are now in Leukemia therapy, including G-CSF, Sorafenib, Venetoclax, MDM2- and IAP- and menin-inhibitors, as well first-in-class MYC/GSPT1 degraders.. Dr. Andreeff has authored >800 publications, including pre-clinical and clinical studies on the therapy of myeloid and lymphoid leukemias. He also developed a pioneering technology for the therapy of solid tumors involving gene-modified mesenchymal stem cells, that convert immunologically "cold" into "hot" tumors.
Education & Training
University of Heidelberg Medical SchoolPh.D., Cell Biology, 1971 - 1976
University of Heidelberg Faculty of MedicineClass of 1968
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 1991 - 2025
Clinical Trials
- IUdR/BUdR Cell Cycle Labelling Start of enrollment: 1992 May 01
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) Start of enrollment: 1998 Mar 01
- Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations Start of enrollment: 2010 Oct 29
Publications & Presentations
PubMed
- A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome.Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour
Haematologica. 2025-02-20 - A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms.Ian M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, Naval Daver, Elias Jabbour
Leukemia. 2025-02-01 - Protocol for monitoring clonal hematopoiesis in transgenic mouse models using multispectral imaging.Priyanka Khanna, Lauren B Ostermann, Shayaun Khazaei, Ran Zhao, Michael Andreeff
STAR Protocols. 2024-12-20
Journal Articles
- Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular SubtypesKoichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
- NSG-S Mice for Acute Myeloid Leukemia, Yes. For Myelodysplastic Syndrome, NoMichael Andreeff, MD, Haematologica
- PTEN Status Is a Crucial Determinant of the Functional Outcome of Combined MEK and mTOR Inhibition in CancerMichael Andreeff, Marina Konopleva, Nature
Abstracts/Posters
- Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem CellsMichael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML CellsMichael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell LymphomasMichael Andreeff, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndr...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Diverse Landscape of TET2 Variants in MDS and AML2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
- MCL-1 up-Regulation Through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML ModelsOctober 2017
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
Press Mentions
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AMLNovember 18th, 2024- MD Anderson Research Highlights for February 22, 2023February 22nd, 2023
- Is Leukemia Truly Incurable and Fatal?January 14th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
